Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance program

SMITHS FALLS, ON, June 5, 2019 /PRNewswire/ – Spectrum Therapeutics (“Spectrum”), the medical division of Canopy Growth Corporation (WEED.TO) (CGC) (the “Company” or “Canopy Growth”) is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines through clinical trials. With a highly experienced scientific team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws.

READ MORE: https://finance.yahoo.com/news/spectrum-therapeutics-provides-global-clinical-110000223.html?.tsrc=rss